<DOC>
	<DOC>NCT00435669</DOC>
	<brief_summary>The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664</brief_summary>
	<brief_title>A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)</brief_title>
	<detailed_description />
	<criteria>Histologic/cytologic diagnosis of advanced or metastatic solid tumors ECOG 02 4/6 weeks since prior therapy Brain metastases Secondary primary malignancy Thromboembolic disease requiring full anticoagulation within 6 months Inability to swallow or absorb oral therapy Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>Advanced or metastatic solid tumors</keyword>
</DOC>